The report is here (just for $4850!!!):
The global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs was valued at $34.9 billion in 2011. This figure is projected to reach $38 billion in 2012 and $47.1 billion in 2017, increasing at a five-year compound annual growth rate (CAGR) of 4.4%.Combination asthma/COPD drugs are expected to be worth $17.4 billion in 2012 and should reach $21.3 billion in 2017, a CAGR of 4.1%.
The segment made up of asthma drugs is projected to increase from $15.3 billion in 2012 to $20.2 billion in 2017, a CAGR of 5.7%.
COPD drugs are expected to increase from $5.3 billion in 2012 to $5.6 billion in 2017, a CAGR of 1.2%.
The global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs was valued at $34.9 billion in 2011. This figure is projected to reach $38 billion in 2012 and $47.1 billion in 2017, increasing at a five-year compound annual growth rate (CAGR) of 4.4%.
No comments:
Post a Comment